36 results on '"McMurray, John J. V."'
Search Results
2. Transcatheter Repair ofSecondary Mitral Regurgitation.
- Author
-
McMurray, John J. V. and Metra, Marco
- Abstract
An editorial is presented that 5-year follow-up of the COAPT trial, which demonstrated that transcatheter repair of the mitral valve in patients with heart failure and secondary mitral regurgitation led to significant reductions in hospitalization rates and mortality. Topics include the importance of functional mitral regurgitation in heart failure progression, the need for guideline-recommended therapies and the potential benefits of transcatheter intervention in reducing mitral regurgitation.
- Published
- 2023
- Full Text
- View/download PDF
3. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
- Author
-
McMurray, John J. V., Solomon, Scott D., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Anand, Inder S., Bělohlávek, Jan, Böhm, Michael, Chiang, Chern-En, Chopra, Vijay K., de Boer, Rudolf A., Desai, Akshay S., Diez, Mirta, Drozdz, Jaroslaw, Dukát, Andrej, Ge, Junbo, and Howlett, Jonathan G.
- Abstract
BACKGROUND In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes. METHODS In this phase 3, placebo-controlled trial, we randomly assigned 4744 patients with New York Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either dapagliflozin (at a dose of 10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or cardiovascular death. RESULTS Over a median of 18.2 months, the primary outcome occurred in 386 of 2373 patients (16.3%) in the dapagliflozin group and in 502 of 2371 patients (21.2%) in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P<0.001). A first worsening heart failure event occurred in 237 patients (10.0%) in the dapagliflozin group and in 326 patients (13.7%) in the placebo group (hazard ratio, 0.70; 95% CI, 0.59 to 0.83). Death from cardiovascular causes occurred in 227 patients (9.6%) in the dapagliflozin group and in 273 patients (11.5%) in the placebo group (hazard ratio, 0.82; 95% CI, 0.69 to 0.98); 276 patients (11.6%) and 329 patients (13.9%), respectively, died from any cause (hazard ratio, 0.83; 95% CI, 0.71 to 0.97). Findings in patients with diabetes were similar to those in patients without diabetes. The frequency of adverse events related to volume depletion, renal dysfunction, and hypoglycemia did not differ between treatment groups. CONCLUSIONS Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
4. Lessons in Uncertainty and Humility - Clinical Trials Involving Hypertension.
- Author
-
Pfeffer, Marc A. and McMurray, John J. V.
- Subjects
- *
HYPERTENSION , *THERAPEUTICS , *CLINICAL trials , *ANTIHYPERTENSIVE agents , *PLACEBOS , *CARDIOVASCULAR agents , *BLOOD pressure - Abstract
The article looks at some examples from cardiovascular medicine to discuss the impact of the existing and evolving information on trial design concerning the choice of placebo or active comparator agents. Topics mentioned include the use of surrogate measures to direct therapeutic decisions, early data on blood pressure and outcomes, and a graph that shows trials influencing blood-pressure thresholds at which antihypertensive medications should be used.
- Published
- 2016
- Full Text
- View/download PDF
5. Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure.
- Author
-
McMurray, John J. V., Krum, Henry, Abraham, William T., Dickstein, Kenneth, Kober, Lars V., Desai, Akshay S., Solomon, Scott D., Greenlaw, Nicola, Ali, M. Atif, Yanntong Chiang, Qing Shao, Tamesby, Georgia, Massie, Barry M., Køber, Lars V, Chiang, Yanntong, Shao, Qing, Tarnesby, Georgia, and ATMOSPHERE Committees Investigators
- Subjects
- *
ALISKIREN , *ENALAPRIL , *HEART failure treatment , *HEALTH outcome assessment , *ACE inhibitors , *TYPE 2 diabetes complications , *AMIDES , *COMBINATION drug therapy , *CHRONIC diseases , *COMPARATIVE studies , *HEART failure , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *TYPE 2 diabetes , *RENIN , *RESEARCH , *EVALUATION research , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *BLIND experiment , *ACYCLIC acids , *STROKE volume (Cardiac output) , *KAPLAN-Meier estimator , *DISEASE complications , *THERAPEUTICS - Abstract
Background: Among patients with chronic heart failure, angiotensin-converting-enzyme (ACE) inhibitors reduce mortality and hospitalization, but the role of a renin inhibitor in such patients is unknown. We compared the ACE inhibitor enalapril with the renin inhibitor aliskiren (to test superiority or at least noninferiority) and with the combination of the two treatments (to test superiority) in patients with heart failure and a reduced ejection fraction.Methods: After a single-blind run-in period, we assigned patients, in a double-blind fashion, to one of three groups: 2336 patients were assigned to receive enalapril at a dose of 5 or 10 mg twice daily, 2340 to receive aliskiren at a dose of 300 mg once daily, and 2340 to receive both treatments (combination therapy). The primary composite outcome was death from cardiovascular causes or hospitalization for heart failure.Results: After a median follow-up of 36.6 months, the primary outcome occurred in 770 patients (32.9%) in the combination-therapy group and in 808 (34.6%) in the enalapril group (hazard ratio, 0.93; 95% confidence interval [CI], 0.85 to 1.03). The primary outcome occurred in 791 patients (33.8%) in the aliskiren group (hazard ratio vs. enalapril, 0.99; 95% CI, 0.90 to 1.10); the prespecified test for noninferiority was not met. There was a higher risk of hypotensive symptoms in the combination-therapy group than in the enalapril group (13.8% vs. 11.0%, P=0.005), as well as higher risks of an elevated serum creatinine level (4.1% vs. 2.7%, P=0.009) and an elevated potassium level (17.1% vs. 12.5%, P<0.001).Conclusions: In patients with chronic heart failure, the addition of aliskiren to enalapril led to more adverse events without an increase in benefit. Noninferiority was not shown for aliskiren as compared with enalapril. (Funded by Novartis; ATMOSPHERE ClinicalTrials.gov number, NCT00853658.). [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
6. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure.
- Author
-
McMurray, John J. V., Packer, Milton, Desai, Akshay S., Jianjian Gong, Lefkowitz, Martin P., Rizkala, Adel R., Rouleau, Jean L., Shi, Victor C., Solomon, Scott D., Swedberg, Karl, and Zile, Michael R.
- Subjects
- *
ANGIOTENSIN receptors , *NEPRILYSIN , *ENALAPRIL , *HEART failure patients , *HYPOTENSION , *KIDNEY diseases , *THERAPEUTICS - Abstract
The article reports on a trial on using angiotensin receptor-neprilysin inhibitor LCZ696 (L) with enalapril (E) in heart-failure patients with a reduced ejection fraction in 2014. Based on results, L, like E, reduced hospitalization risk by 21% and lessened heart failure symptoms and physical limitation, with the Lgroup having more patients with hypotension and less patients with renal impairment than the E group. L was found to be superior to E in reducing death and hospitalization risks.
- Published
- 2014
- Full Text
- View/download PDF
7. Angiotensin-Neprilys in Inhibition in Heart Failure with Preserved Ejection Fraction.
- Author
-
Solomon, Scott D. and McMurray, John J. V.
- Published
- 2020
- Full Text
- View/download PDF
8. Cardiovascular Risks with Azithromycin.
- Author
-
McMurray, John J. V. and Jhund, Pardeep S.
- Subjects
- *
AZITHROMYCIN , *ANTIBACTERIAL agents , *CARDIOVASCULAR diseases risk factors , *CORONARY disease , *MORTALITY - Abstract
Several letters to the editor and replies are presented concerning the articles "Use of azithromycin death from cardiovascular causes" in the May 2, 2013 issue and "Cardiovascular risks with azithromycin and other antibacterial drugs."
- Published
- 2013
- Full Text
- View/download PDF
9. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.
- Author
-
Singh, Ajay K., Carroll, Kevin, McMurray, John J. V., Solomon, Scott, Jha, Vivekanand, Johansen, Kirsten L., Lopes, Renato D., Macdougall, Iain C., Obrador, Gregorio T., Waikar, Sushrut S., Wanner, Christoph, Wheeler, David C., Wiecek, Andrzej, Blackorby, Allison, Cizman, Borut, Cobitz, Alexander R., Davies, Rich, Di Mino, Tara L., Kler, Lata, and Meadowcroft, Amy M.
- Subjects
- *
CHRONIC kidney failure , *RESEARCH , *HEMATOPOIETIC agents , *GLYCINE , *CLINICAL trials , *STROKE , *HEMOGLOBINS , *RESEARCH methodology , *CARDIOVASCULAR diseases , *MYOCARDIAL infarction , *EVALUATION research , *COMPARATIVE studies , *RANDOMIZED controlled trials , *ANEMIA , *RESEARCH funding , *OXIDOREDUCTASES , *STATISTICAL sampling , *BARBITURATES , *CHEMICAL inhibitors ,CHRONIC kidney failure complications ,CARDIOVASCULAR disease related mortality - Abstract
Background: Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. In patients with chronic kidney disease (CKD) who are not undergoing dialysis, the efficacy and safety of daprodustat, as compared with the conventional erythropoiesis-stimulating agent darbepoetin alfa, are unknown.Methods: In this randomized, open-label, phase 3 trial with blinded adjudication of cardiovascular outcomes, we compared daprodustat with darbepoetin alfa for the treatment of anemia in patients with CKD who were not undergoing dialysis. The primary outcomes were the mean change in the hemoglobin level from baseline to weeks 28 through 52 and the first occurrence of a major adverse cardiovascular event (MACE; a composite of death from any cause, nonfatal myocardial infarction, or nonfatal stroke).Results: Overall, 3872 patients were randomly assigned to receive daprodustat or darbepoetin alfa. The mean (±SD) baseline hemoglobin levels were similar in the two groups. The mean (±SE) change in the hemoglobin level from baseline to weeks 28 through 52 was 0.74±0.02 g per deciliter in the daprodustat group and 0.66±0.02 g per deciliter in the darbepoetin alfa group (difference, 0.08 g per deciliter; 95% confidence interval [CI], 0.03 to 0.13), which met the prespecified noninferiority margin of -0.75 g per deciliter. During a median follow-up of 1.9 years, a first MACE occurred in 378 of 1937 patients (19.5%) in the daprodustat group and in 371 of 1935 patients (19.2%) in the darbepoetin alfa group (hazard ratio, 1.03; 95% CI, 0.89 to 1.19), which met the prespecified noninferiority margin of 1.25. The percentages of patients with adverse events were similar in the two groups.Conclusions: Among patients with CKD and anemia who were not undergoing dialysis, daprodustat was noninferior to darbepoetin alfa with respect to the change in the hemoglobin level from baseline and with respect to cardiovascular outcomes. (Funded by GlaxoSmithKline; ASCEND-ND ClinicalTrials.gov number, NCT02876835.). [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
10. The ICD in Heart Failure - Time for a Rethink?
- Author
-
McMurray, John J. V.
- Subjects
- *
IMPLANTABLE cardioverter-defibrillators , *HEART failure , *CARDIOMYOPATHIES , *ACE inhibitors , *MINERALOCORTICOID receptors , *CARDIAC pacing , *HEART disease related mortality , *PREVENTION , *CARDIAC arrest , *TREATMENT effectiveness - Abstract
The article discusses utilization of implantable cardioverter-defibrillators (ICDs) in management of heart failure. Topics discussed include reduction in premature death by ICDs usage in ventricular systolic dysfunction, involvement of nonischemic cardiomyopathy in patients, usage of angiotensin-converting- enzyme inhibitors along with mineralocorticoid-receptor, description of cardiac-resynchronization therapy for treatment process and implications for reduction in cardiac disease mortality.
- Published
- 2016
- Full Text
- View/download PDF
11. Neprilysin inhibition for heart failure.
- Author
-
McMurray, John J V, Packer, Milton, and Solomon, Scott D
- Published
- 2014
- Full Text
- View/download PDF
12. Clinical Trials Involving Hypertension.
- Author
-
Pfeffer, Marc A. and McMurray, John J. V.
- Subjects
- *
CLINICAL trials , *HYPERTENSION , *UNCERTAINTY - Abstract
A response from the authors of the article "Lessons in uncertainty and humility — clinical trials involving hypertension" in the 2016 issue is presented.
- Published
- 2017
- Full Text
- View/download PDF
13. Lessons from the TOPCAT Trial.
- Author
-
McMurray, John J. V. and O'Connor, Christopher
- Subjects
- *
HEART function tests , *HEART failure , *ALDOSTERONE , *ALDOSTERONE antagonists , *SPIRONOLACTONE , *NATRIURETIC peptides , *THERAPEUTICS - Abstract
The author discusses the lessons learned from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial in the U.S. Topics covered include the reduced potential benefits of spironolactone therapy for heart failure patients and the importance of natriuretic peptide levels as a predictor of adverse outcomes in heart failure patients particularly for those with preserved ejection fraction.
- Published
- 2014
- Full Text
- View/download PDF
14. ECG--still the best for selecting patients for CRT.
- Author
-
Yancy, Clyde W and McMurray, John J V
- Published
- 2013
- Full Text
- View/download PDF
15. Cardiovascular risks with azithromycin.
- Author
-
McMurray, John J V and Jhund, Pardeep S
- Published
- 2013
- Full Text
- View/download PDF
16. Darbepoetin alfa in systolic heart failure.
- Author
-
Swedberg, Karl, McMurray, John J V, and Young, James B
- Published
- 2013
- Full Text
- View/download PDF
17. Systolic Heart Failure.
- Author
-
McMurray, John J. V.
- Subjects
- *
LETTERS to the editor , *HEART failure - Abstract
A response by John J. V. McMurray to a letter to the editor about his article "Systolic Heart Failure," in the January 21, 2010 issue is presented.
- Published
- 2010
- Full Text
- View/download PDF
18. Dapagliflozin in Heart Failure with Preserved Ejection Fraction.
- Author
-
Solornon, Scott D., Vaduganathan, Muthiah, and McMurray, John J. V.
- Subjects
- *
VENTRICULAR ejection fraction , *HEART failure , *DAPAGLIFLOZIN - Published
- 2023
- Full Text
- View/download PDF
19. Pragmatic Trials.
- Author
-
Drazen, Jeffrey M., Harrington, David P., McMurray, John J. V., Ware, James H., Woodcock, Janet, Ford, Ian, and Norrie, John
- Subjects
- *
PRAGMATICS , *PRAGMATISM , *CLINICAL trials , *HEALTH outcome assessment , *INVESTIGATIONAL therapies , *MEDICAL experimentation on humans - Abstract
In pragmatic trials, participants are broadly representative of people who will receive a treatment or diagnostic strategy, and the outcomes affect day-to-day care. The authors review the unique features of pragmatic trials through a wide-ranging series of exemplar trials. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
20. THE AUTHORS REPLY.
- Author
-
Teerlink, John R., Felker, G. Michael, and McMurray, John J. V.
- Subjects
- *
HEART failure , *EMPAGLIFLOZIN , *IVABRADINE , *COVID-19 , *CORONARY disease - Abstract
The article argues over the comment that lack of effect on cardiovascular mortality in GALACTIC-HF is due to an unfavorable effect of omecamtiv mecarbil on myocardial energetics, citing work in a model of acute ischemia in pigs and in whole hearts subjected to cardioplegia. Topics include deficiencies in the experimental approach undermine the conclusions contradictory to the lack of effect of omecamtiv mecarbil; and myocardial oxygen consumption and its inhibition of the resting myosin ATPase.
- Published
- 2021
- Full Text
- View/download PDF
21. TO THE EDITOR.
- Author
-
Docherty, Kieran F., Jhund, Pardeep S., and McMurray, John J. V.
- Published
- 2018
- Full Text
- View/download PDF
22. Dapagliflozin in Patients with Chronic Kidney Disease.
- Author
-
Heerspink, Hiddo J. L., Stefánsson, Bergur V., Correa-Rotter, Ricardo, Chertow, Glenn M., Greene, Tom, Fan-Fan Hou, Mann, Johannes F. E., McMurray, John J. V., Lindberg, Magnus, Rossing, Peter, Sjöström, C. David, Toto, Roberto D., Langkilde, Anna-Maria, Wheeler, David C., Hou, Fan-Fan, and DAPA-CKD Trial Committees and Investigators
- Subjects
- *
CARDIOVASCULAR disease prevention , *BENZENE , *CHRONIC kidney failure , *GLOMERULAR filtration rate , *RESEARCH , *RESEARCH methodology , *GLYCOSIDES , *CARDIOVASCULAR diseases , *REGRESSION analysis , *EVALUATION research , *MEDICAL cooperation , *TYPE 2 diabetes , *COMPARATIVE studies , *RANDOMIZED controlled trials , *KAPLAN-Meier estimator , *RESEARCH funding , *DIABETIC nephropathies , *DISEASE complications ,CHRONIC kidney failure complications ,CARDIOVASCULAR disease related mortality - Abstract
Background: Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known.Methods: We randomly assigned 4304 participants with an estimated glomerular filtration rate (GFR) of 25 to 75 ml per minute per 1.73 m2 of body-surface area and a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of 200 to 5000 to receive dapagliflozin (10 mg once daily) or placebo. The primary outcome was a composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes.Results: The independent data monitoring committee recommended stopping the trial because of efficacy. Over a median of 2.4 years, a primary outcome event occurred in 197 of 2152 participants (9.2%) in the dapagliflozin group and 312 of 2152 participants (14.5%) in the placebo group (hazard ratio, 0.61; 95% confidence interval [CI], 0.51 to 0.72; P<0.001; number needed to treat to prevent one primary outcome event, 19 [95% CI, 15 to 27]). The hazard ratio for the composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal causes was 0.56 (95% CI, 0.45 to 0.68; P<0.001), and the hazard ratio for the composite of death from cardiovascular causes or hospitalization for heart failure was 0.71 (95% CI, 0.55 to 0.92; P = 0.009). Death occurred in 101 participants (4.7%) in the dapagliflozin group and 146 participants (6.8%) in the placebo group (hazard ratio, 0.69; 95% CI, 0.53 to 0.88; P = 0.004). The effects of dapagliflozin were similar in participants with type 2 diabetes and in those without type 2 diabetes. The known safety profile of dapagliflozin was confirmed.Conclusions: Among patients with chronic kidney disease, regardless of the presence or absence of diabetes, the risk of a composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes was significantly lower with dapagliflozin than with placebo. (Funded by AstraZeneca; DAPA-CKD ClinicalTrials.gov number, NCT03036150.). [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
23. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.
- Author
-
Vaduganathan, Muthiah, Vardeny, Orly, Michel, Thomas, McMurray, John J. V., Pfeffer, Marc A., and Solomon, Scott D.
- Subjects
- *
ANGIOTENSIN converting enzyme , *ACE inhibitors , *BIOCHEMISTRY , *CHRONIC kidney failure , *EPIDEMICS , *HYPERTENSION , *PHENOMENOLOGY , *RENIN-angiotensin system , *ANGIOTENSIN receptors , *COVID-19 , *DISEASE complications , *PHARMACODYNAMICS ,CHRONIC kidney failure complications - Abstract
In this article the author talks about the study of the renin-angiotensin-aldosterone system (RAAS) which is an elegant cascade of vasoactive peptides that orchestrate key processes in human physiology. Topics discussed Tissue-specific and circulating components of RAAS make up complex intersecting network of regulatory, and switching from a RAAS inhibitor to another antihypertensive therapy in a stable ambulatory patient require careful follow-up to avoid rebound increases in blood pressure.
- Published
- 2020
- Full Text
- View/download PDF
24. Declining Risk of Sudden Death in Heart Failure.
- Author
-
Shen Li, Jhund, Pardeep S., and McMurray, John J. V.
- Subjects
- *
SUDDEN death , *LINEAR statistical models , *REGRESSION analysis - Published
- 2017
- Full Text
- View/download PDF
25. Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.
- Author
-
Macdougall, Iain C., White, Claire, Anker, Stefan D., Bhandari, Sunil, Farrington, Kenneth, Kalra, Philip A., McMurray, John J. V., Murray, Heather, Tomson, Charles R. V., Wheeler, David C., Winearls, Christopher G., Ford, Ian, and PIVOTAL Investigators and Committees
- Abstract
Background: Intravenous iron is a standard treatment for patients undergoing hemodialysis, but comparative data regarding clinically effective regimens are limited.Methods: In a multicenter, open-label trial with blinded end-point evaluation, we randomly assigned adults undergoing maintenance hemodialysis to receive either high-dose iron sucrose, administered intravenously in a proactive fashion (400 mg monthly, unless the ferritin concentration was >700 μg per liter or the transferrin saturation was ≥40%), or low-dose iron sucrose, administered intravenously in a reactive fashion (0 to 400 mg monthly, with a ferritin concentration of <200 μg per liter or a transferrin saturation of <20% being a trigger for iron administration). The primary end point was the composite of nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, or death, assessed in a time-to-first-event analysis. These end points were also analyzed as recurrent events. Other secondary end points included death, infection rate, and dose of an erythropoiesis-stimulating agent. Noninferiority of the high-dose group to the low-dose group would be established if the upper boundary of the 95% confidence interval for the hazard ratio for the primary end point did not cross 1.25.Results: A total of 2141 patients underwent randomization (1093 patients to the high-dose group and 1048 to the low-dose group). The median follow-up was 2.1 years. Patients in the high-dose group received a median monthly iron dose of 264 mg (interquartile range [25th to 75th percentile], 200 to 336), as compared with 145 mg (interquartile range, 100 to 190) in the low-dose group. The median monthly dose of an erythropoiesis-stimulating agent was 29,757 IU in the high-dose group and 38,805 IU in the low-dose group (median difference, -7539 IU; 95% confidence interval [CI], -9485 to -5582). A total of 320 patients (29.3%) in the high-dose group had a primary end-point event, as compared with 338 (32.3%) in the low-dose group (hazard ratio, 0.85; 95% CI, 0.73 to 1.00; P<0.001 for noninferiority; P=0.04 for superiority). In an analysis that used a recurrent-events approach, there were 429 events in the high-dose group and 507 in the low-dose group (rate ratio, 0.77; 95% CI, 0.66 to 0.92). The infection rate was the same in the two groups.Conclusions: Among patients undergoing hemodialysis, a high-dose intravenous iron regimen administered proactively was superior to a low-dose regimen administered reactively and resulted in lower doses of erythropoiesis-stimulating agent being administered. (Funded by Kidney Research UK; PIVOTAL EudraCT number, 2013-002267-25 .). [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
26. Clinical Trials Involving Hypertension.
- Author
-
Paton, David M., Pfeffer, Marc A, and McMurray, John J V
- Subjects
- *
HYPERTENSION , *THERAPEUTICS , *ANTIHYPERTENSIVE agents , *CLINICAL trials - Abstract
A letter to the editor is presented in response to the article "Lessons in uncertainty and humility — clinical trials involving hypertension," by Marc A. Pfeffer and John J. V. McMurray in the November 3, 2016 issue.
- Published
- 2017
- Full Text
- View/download PDF
27. Aliskiren in type 2 diabetes and cardiorenal end points.
- Author
-
Pfeffer, Marc A, Brenner, Barry M, and McMurray, John J V
- Published
- 2013
- Full Text
- View/download PDF
28. Clinical Trials Series.
- Author
-
Woodcock, Janet, Miller, Pamela W., McMurray, John J. V., Harrington, David P., and Drazen, Jeffrey M.
- Abstract
An introduction is presented in which the author discusses various reports within the issue on topics which include examining the challenges in the design, performance and interpretation of clinical trials, integrating comparative trials into patient care, and using trial data in decision making.
- Published
- 2016
- Full Text
- View/download PDF
29. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
- Author
-
Pfeffer, Marc A., Claggett, Brian, Diaz, Rafael, Dickstein, Kenneth, Gerstein, Hertzel C., Kober, Lars V., Lawson, Francesca C., Lin Ping, Xiaodan Wei, Lewis, Eldrin F., Maggioni, Aldo P., McMurray, John J. V., Probstfield, Jeffrey L., Riddle, Matthew C., Solomon, Scott D., Tardif, Jean-Claude, Køber, Lars V, Ping, Lin, Wei, Xiaodan, and ELIXA Investigators
- Subjects
- *
CARDIOVASCULAR disease prevention , *MYOCARDIAL infarction complications , *TYPE 2 diabetes complications , *ANGINA pectoris , *CARDIOVASCULAR diseases , *COMPARATIVE studies , *GLYCOSYLATED hemoglobin , *HYPOGLYCEMIC agents , *RESEARCH methodology , *MEDICAL cooperation , *TYPE 2 diabetes , *PEPTIDES , *RESEARCH , *RESEARCH funding , *EVALUATION research , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *PROPORTIONAL hazards models , *ACUTE coronary syndrome , *KAPLAN-Meier estimator , *DISEASE complications , *THERAPEUTICS - Abstract
Background: Cardiovascular morbidity and mortality are higher among patients with type 2 diabetes, particularly those with concomitant cardiovascular diseases, than in most other populations. We assessed the effects of lixisenatide, a glucagon-like peptide 1-receptor agonist, on cardiovascular outcomes in patients with type 2 diabetes who had had a recent acute coronary event.Methods: We randomly assigned patients with type 2 diabetes who had had a myocardial infarction or who had been hospitalized for unstable angina within the previous 180 days to receive lixisenatide or placebo in addition to locally determined standards of care. The trial was designed with adequate statistical power to assess whether lixisenatide was noninferior as well as superior to placebo, as defined by an upper boundary of the 95% confidence interval for the hazard ratio of less than 1.3 and 1.0, respectively, for the primary composite end point of cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina.Results: The 6068 patients who underwent randomization were followed for a median of 25 months. A primary end-point event occurred in 406 patients (13.4%) in the lixisenatide group and in 399 (13.2%) in the placebo group (hazard ratio, 1.02; 95% confidence interval [CI], 0.89 to 1.17), which showed the noninferiority of lixisenatide to placebo (P<0.001) but did not show superiority (P=0.81). There were no significant between-group differences in the rate of hospitalization for heart failure (hazard ratio in the lixisenatide group, 0.96; 95% CI, 0.75 to 1.23) or the rate of death (hazard ratio, 0.94; 95% CI, 0.78 to 1.13). Lixisenatide was not associated with a higher rate of serious adverse events or severe hypoglycemia, pancreatitis, pancreatic neoplasms, or allergic reactions than was placebo.Conclusions: In patients with type 2 diabetes and a recent acute coronary syndrome, the addition of lixisenatide to usual care did not significantly alter the rate of major cardiovascular events or other serious adverse events. (Funded by Sanofi; ELIXA ClinicalTrials.gov number, NCT01147250.). [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
30. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
- Author
-
Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJV, RECORD Study Group, Home, Philip D, Pocock, Stuart J, Beck-Nielsen, Henning, Gomis, Ramón, Hanefeld, Markolf, Jones, Nigel P, Komajda, Michel, and McMurray, John J V
- Abstract
Background: A recent meta-analysis raised concern regarding an increased risk of myocardial infarction and death from cardiovascular causes associated with rosiglitazone treatment of type 2 diabetes.Methods: We conducted an unplanned interim analysis of a randomized, multicenter, open-label, noninferiority trial involving 4447 patients with type 2 diabetes who had inadequate glycemic control while receiving metformin or sulfonylurea, in which 2220 patients were assigned to receive add-on rosiglitazone (rosiglitazone group), and 2227 to receive a combination of metformin plus sulfonylurea (control group). The primary end point was hospitalization or death from cardiovascular causes.Results: Because the mean follow-up was only 3.75 years, our interim analysis had limited statistical power to detect treatment differences. A total of 217 patients in the rosiglitazone group and 202 patients in the control group had the adjudicated primary end point (hazard ratio, 1.08; 95% confidence interval [CI], 0.89 to 1.31). After the inclusion of end points pending adjudication, the hazard ratio was 1.11 (95% CI, 0.93 to 1.32). There were no statistically significant differences between the rosiglitazone group and the control group regarding myocardial infarction and death from cardiovascular causes or any cause. There were more patients with heart failure in the rosiglitazone group than in the control group (hazard ratio, 2.15; 95% CI, 1.30 to 3.57).Conclusions: Our interim findings from this ongoing study were inconclusive regarding the effect of rosiglitazone on the overall risk of hospitalization or death from cardiovascular causes. There was no evidence of any increase in death from either cardiovascular causes or all causes. Rosiglitazone was associated with an increased risk of heart failure. The data were insufficient to determine whether the drug was associated with an increase in the risk of myocardial infarction. (ClinicalTrials.gov number, NCT00379769 [ClinicalTrials.gov].). [ABSTRACT FROM AUTHOR]- Published
- 2007
31. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
- Author
-
Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau J, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, Valsartan in Acute Myocardial Infarction Trial Investigators, Pfeffer, Marc A, McMurray, John J V, and Velazquez, Eric J
- Abstract
Background: Angiotensin-converting-enzyme (ACE) inhibitors such as captopril reduce mortality and cardiovascular morbidity among patients with myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. In a double-blind trial, we compared the effect of the angiotensin-receptor blocker valsartan, the ACE inhibitor captopril, and the combination of the two on mortality in this population of patients.Methods: Patients receiving conventional therapy were randomly assigned, 0.5 to 10 days after acute myocardial infarction, to additional therapy with valsartan (4909 patients), valsartan plus captopril (4885 patients), or captopril (4909 patients). The primary end point was death from any cause.Results: During a median follow-up of 24.7 months, 979 patients in the valsartan group died, as did 941 patients in the valsartan-and-captopril group and 958 patients in the captopril group (hazard ratio in the valsartan group as compared with the captopril group, 1.00; 97.5 percent confidence interval, 0.90 to 1.11; P=0.98; hazard ratio in the valsartan-and-captopril group as compared with the captopril group, 0.98; 97.5 percent confidence interval, 0.89 to 1.09; P=0.73). The upper limit of the one-sided 97.5 percent confidence interval for the comparison of the valsartan group with the captopril group was within the prespecified margin for noninferiority with regard to mortality (P=0.004) and with regard to the composite end point of fatal and nonfatal cardiovascular events (P<0.001). The valsartan-and-captopril group had the most drug-related adverse events. With monotherapy, hypotension and renal dysfunction were more common in the valsartan group, and cough, rash, and taste disturbance were more common in the captopril group.Conclusions: Valsartan is as effective as captopril in patients who are at high risk for cardiovascular events after myocardial infarction. Combining valsartan with captopril increased the rate of adverse events without improving survival. [ABSTRACT FROM AUTHOR]- Published
- 2003
32. Aliskiren in Type 2 Diabetes and Cardiorenal End Points.
- Author
-
Onuigbo, MacauLay, Xin Du, Zhenjie Chen, Binbin Pan, Pfeffer, Marc A., Brenner, Barry M., and McMurray, John J. V.
- Subjects
- *
ALISKIREN , *TYPE 2 diabetes , *RENIN-angiotensin system , *THERAPEUTICS - Abstract
This section presents letters to the editor about the article "Cardiorenal end points in a trial of aliskiren for type 2 diabetes" by H. H. Parving et al. in the December 6, 2012 issue and the authors' reply which justified that their trial tested whether the addition of the direct renin inhibitor aliskiren to another inhibitor of the renin-angiotensin system would lower morbidity and mortality among patients with type 2 diabetes at high risk for clinically crucial adverse cardiorenal events.
- Published
- 2013
- Full Text
- View/download PDF
33. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. Reply.
- Author
-
McMurray, JohnJ. V., Docherty, Kieran F., Jhund, Pardeep S., and McMurray, John J V
- Subjects
- *
HEART ventricle diseases , *BENZENE , *GLYCOSIDES , *LEFT heart ventricle , *HEART failure , *STROKE volume (Cardiac output) - Abstract
The article presents the views of the authors related to dapagliflozin reducing levels of serum urate seems the mechanism proposed by Borghi and Cicero explaining the benefits of dapagliflozin.
- Published
- 2020
- Full Text
- View/download PDF
34. Aliskiren, Enalapril, or Both in Heart Failure.
- Author
-
Silva, Alessandra R., Martini, Alexandre, Neves, Francisco A. R., McMurray, John J V, Dickstein, Kenneth, and Køber, Lars V
- Subjects
- *
ACE inhibitors , *AMIDES , *ACYCLIC acids , *ENALAPRIL , *HEART failure , *RENIN , *THERAPEUTICS - Abstract
A letter to the editor is presented in response to the article "Aliskiren, enalapril, or aliskiren and enalapril in heart failure" by John J. V. McMurray, and colleagues in the April 21, 2016 issue.
- Published
- 2016
- Full Text
- View/download PDF
35. Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan.
- Author
-
Claggett, Brian, Packer, Milton, Solomon, Scott D., McMurray, John J V, Swedberg, Karl, Rouleau, Jean, Zile, Michael R, Jhund, Pardeep, Lefkowitz, Martin, Shi, Victor, and PARADIGM-HF Investigators
- Abstract
A letter to the editor is presented in response to a study estimating the long-term treatment benefits of sacubitril-valsartan in reducing the rates of death from cardiovascular causes or hospitalization for heart failure.
- Published
- 2015
- Full Text
- View/download PDF
36. Declining Risk of Sudden Death in Heart Failure.
- Author
-
McCarthy, Cian P., McCarthy, Killian J., McEvoy, John W., Shen, Li, Jhund, Pardeep S, and McMurray, John J V
- Subjects
- *
SUDDEN death , *HEART failure , *IMPLANTABLE cardioverter-defibrillators , *CARDIAC arrest , *RELATIVE medical risk ,RISK factors - Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.